Oxazine derivatives of γ-and δ-tocotrienol display enhanced anticancer activity in vivo

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2715-2726

  Ananthula, Suryatheja ^a   Parajuli, Parash ^a   Behery, Fathy A ^a   Alayoubi, Alaadin Y ^a   El Sayed, Khalid A ^a   Nazzal, Sami ^a   Sylvester, Paul W ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

AKT; Breast cancer; Lipid nanoemulsion; NF B.; Oxazine derivatives; Tocotrienols; Vitamin E

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLOOXYGENASE 2; DELTA TOCOTRIENOL; GAMMA TOCOTRIENOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXAZINE DERIVATIVE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; TETRAZOLIUM; TOCOPHEROL DERIVATIVE; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; CHROMAN DERIVATIVE; DRUG DERIVATIVE; PLASTOCHROMANOL 8; TOCOTRIENOL, DELTA; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; ADENOCARCINOMA; AKT; ANIMAL; BAGG ALBINO MOUSE; BREAST CANCER; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL MAMMARY NEOPLASM; LIPID NANOEMULSION; METABOLISM; NFΚB; OXAZINE DERIVATIVES; PATHOLOGY; WESTERN BLOTTING;

AKT; BREAST CANCER; LIPID NANOEMULSION; NFΚB; OXAZINE DERIVATIVES; TOCOTRIENOLS; VITAMIN E;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMANS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; OXAZINES; TUMOR MARKERS, BIOLOGICAL; VITAMIN E;

EID: 84906317330     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Neuzil J, Kagedal K, Andera L, Weber C and Brunk UT: Vitamin E analogs: A new class of multiple action agents with antineo-plastic and anti-atherogenic activity. Apoptosis 7: 179-187, 2002.
2. Sylvester PW and Theriault A: Role of tocotrienols in the prevention of cardiovascular disease and breast cancer. Curr Top Nutraceutical Res 1: 121-136, 2003.
3. Sen CK, Khanna S and Roy S: Tocotrienols in health and disease: The other half of the natural vitamin E family. Mol Aspects Med 28: 692-728, 2007.
4. McIntyre BS, Briski KP, Gapor A and Sylvester PW: Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 224: 292-301, 2000.
5. McIntyre BS, Briski KP, Tirmenstein MA, Fariss MW, Gapor A and Sylvester PW: Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 35: 171-180, 2000.
6. Birringer M, EyTina JH, Salvatore BA and Neuzil J: Vitamin E analogues as inducers of apoptosis: Structure-function relation. Br J Cancer 88: 1948-1955, 2003.
7. Behery FA, Elnagar AY, Akl MR, Wali VB, Abuasal B, Kaddoumi A, Sylvester PW and El Sayed KA: Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors. Bioorg Med Chem 18: 8066-8075, 2010.
8. Behery FA, Akl MR, Ananthula S, Parajuli P, Sylvester PW and El Sayed KA: Optimization of tocotrienols as antiproliferative and antimigratory leads. Eur J Med Chem 59: 329-341, 2013.
9. Hayes KC, Pronczuk A and Liang JS: Differences in the plasma transport and tissue concentrations of tocopherols and tocotrienols: Observations in humans and hamsters. Proc Soc Exp Biol Med 202: 353-359, 1993.
10. Yap SP, Yuen KH and Wong JW: Pharmacokinetics and bioavailability of alpha-, gamma-, and delta-tocotrienols under different food status. J. Pharmaceut. Pharmacol 56: 67-71, 2001.
11. Abuasal B, Sylvester PW and Kaddoumi A: Intestinal absorption of gamma-tocotrienol is mediated by Niemann-Pick C1-like 1: In situ rat intestinal perfusion studies. Drug Metab Dispos 38: 939-945, 2010.
12. Alayoubi A, Nazzal M, Sylvester PW and Nazzal S: Vitamin E'-fortified parenteral lipid emulsions: Plackett-Burman screening of primary process and composition parameters. Drug Dev Ind Pharm 39: 363-373, 2013.
13. Alayoubi A, Kanthala S, Satyanarayanajois SD, Anderson JF, Sylvester PW and Nazzal S: Stability and in vitro antiproliferative activity of bioactive 'vitamin E'-fortified parenteral lipid emulsions. Colloids Surf B Biointerfaces 103: 23-30, 2013.
14. Mendes S, Graziani SR, Vitorio TS, Padoveze AF, Hegg R, Bydlowski SP and Maranhao RC: Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: A new strategy for neoadjuvant chemotherapy. Gynecol Oncol 112: 400-404, 2009.
15. Anderson LW, Danielson KG and Hosick HL: New cell line. Epithelial cell line and subline established from premalignant mouse mammary tissue. In Vitro 15: 841-843, 1979.
16. Anderson LW, Danielson KG and Hosick HL: Metastatic potential of hyperplastic alveolar nodule derived mouse mammary tumor cells following intravenous inoculation. Eur J Cancer Clin Oncol 17: 1001-1008, 1981.
17. Danielson KG, Anderson LW and Hosick HL: Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res 40: 1812-1819, 1980.
18. Shah S, Gapor A and Sylvester PW: Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr Cancer 45: 236-246, 2003.
19. Bachawal SV, Wali VB and Sylvester PW: Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 10: 84, 2010.
20. Jumaa M and Muller BW: Development of a novel parenteral formulation for tetrazepam using a lipid emulsion. Drug Dev Ind Pharm 27: 1115-1121, 2001.
21. Sylvester PW: Vitamin E-induced apoptosis in mouse mammary tumors. In: New Cell Apoptosis Research. Valentino RG (ed.). New York, Nova Science Publisher, Inc., pp. 53-68, 2007.
22. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
23. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
24. Bernardi DS, Pereira TA, Maciel NR, Bortoloto J, Viera GS, Oliveira GC and Rocha-Filho PA: Formation and stability of oil-in-water nanoemulsions containing rice bran oil: In vitro and in vivo assessments. J Nanobiotechnology 9: 44, 2011.
25. Constantinides PP, Tustian A and Kessler DR: Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev 56: 1243-1255, 2004.
26. Cheong JN, Tan CP, Man YBC and Misran M: Gamma-tocopherol nanodispersions: Preparation, characterization and stability evaluation. J Food Engineer 89: 204-209, 2008.
27. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ and Kato JY: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14: 2066-2076, 1994.
28. Sherr CJ: Principles of tumor suppression. Cell 116: 235-246, 2004.
29. Ekholm SV and Reed SI: Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12: 676-684, 2000.
30. Caldon CE, Daly RJ, Sutherland RL and Musgrove EA: Cell cycle control in breast cancer cells. J Cell Biochem 97: 261-274, 2006.
31. Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv Cancer Res 68: 67-108, 1996.
32. Haefner B: Targeting NF-kappaB in anticancer adjunctive chemotherapy. Cancer Treat Res 130: 219-245, 2006.
33. Brown K, Park S, Kanno T, Franzoso G and Siebenlist U: Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha. Proc Natl Acad Sci USA 90: 2532-2536, 1993.
34. Biswas DK, Cruz AP, Gansberger E and Pardee AB: Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97: 8542-8547, 2000.
35. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr. and Sledge GW Jr.: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17: 3629-3639, 1997.
36. Downward J: Mechanisms and consequences of activation of protein kinase B/AKT. Curr Opin Cell Biol 10: 262-267, 1998.
37. Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG and Anderson KC: Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/AKT signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 21: 5673-5683, 2002.
38. Grandage VL, Gale RE, Linch DC and Khwaja A: PI3-kinase/AKT is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, MAP kinase and p53 pathways. Leukemia 19: 586-594, 2005.
39. Massague J: G1 cell-cycle control and cancer. Nature 432: 298-306, 2004.
40. Samant G V, Wali VB and Sylvester PW: Anti-proliferative effects of gamma-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif 43: 77-83, 2009.
41. Samant GV and Sylvester PW: Gamma-tocotrienol inhibits ERBB3-dependent PI3k/AKT mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif 39: 563-574, 2006.
42. Bachawal SV, Wali VB and Sylvester PW: Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses STAT and AKT signaling in murine mammary tumor cells. Anticancer Res 30: 429-437, 2010.
43. Ayoub NM, Bachawal SV and Sylvester PW: Gamma-tocotrienol inhibits HGF-dependent mitogenesis and MET activation in highly malignant mammary tumour cells. Cell Prolif 44: 516-526, 2011.